Lihong Sun
Broker in Lexington, MA
License number
Massachusetts 9552161
Issued Date
Aug 11, 2016
Expiration Date
Jul 31, 2019
Type
Salesperson
Address
Address
Lexington, MA 02421
Professional information
Substituted Pyrazalones
US Patent:
2010005, Mar 4, 2010
Filed:
Nov 21, 2006
Appl. No.:
12/085380
Inventors:
Mary Beth Carter - Lawrence KS, US
Claudio Chuaqui - Arlington MA, US
Kevin Guckian - Marlborough MA, US
Edward Lin - Chesnut Hill MA, US
Michael J. Choi - San Diego CA, US
Zhan Deng - Winchester MA, US
Lihong Sun - Lexington MA, US
Claudio Chuaqui - Arlington MA, US
Kevin Guckian - Marlborough MA, US
Edward Lin - Chesnut Hill MA, US
Michael J. Choi - San Diego CA, US
Zhan Deng - Winchester MA, US
Lihong Sun - Lexington MA, US
International Classification:
A61K 31/498, C07D 403/02, C07D 401/14, C07D 409/14, C07D 403/12, C07D 417/14, C07D 413/14, A61K 31/541, A61K 31/5377, A61P 43/00, A61P 35/00, A61P 9/00, A61P 9/12
US Classification:
5142282, 544353, 544 581, 544116, 514249, 5142348
Abstract:
The invention is related to compounds of formula (I) as antagonists of the TGFβ family type I receptors, Alk5 and/or AIk 4, compositions and methods of use. The compounds of formula (I) can be employed in the prevention and/or treatment of diseases such as fibrosis (e.g., renal fibrosis, pulmonary fibrosis, and hepatic fibrosis), progressive cancers, or other diseases for which reduction of TGFβ family signaling activity is desirable.
Furanone Compounds And Methods Of Making And Using The Same
US Patent:
2010010, Apr 29, 2010
Filed:
Jan 30, 2008
Appl. No.:
12/525144
Inventors:
Lihong Sun - Lexington MA, US
Paul Lyne - Arlington MA, US
Paul Lyne - Arlington MA, US
Assignee:
Biogen Idec MA Inc. - Cambridge
International Classification:
A61K 31/438, C07D 307/02, A61K 31/34, C07D 471/10, C07D 471/04, A61K 31/437
US Classification:
514278, 549479, 514473, 546 16, 546119, 514303
Abstract:
The invention features compounds of the general Formula (I): (formula should be inserted here) Compounds of Formula (I) possess unexpectedly high affinity for Alk5 and/or Alk4, and can be useful as antagonists thereof for preventing and/or treating numerous diseases, including fibrotic disorders.
Transforming Growth Factor Modulators
US Patent:
2010016, Jul 1, 2010
Filed:
Dec 22, 2006
Appl. No.:
12/086954
Inventors:
Lihong Sun - Lexington MA, US
Michael Hoemann - Marlborough MA, US
Deqiang Niu - Lexington MA, US
Dingxue Yan - Grafton MA, US
Claudio Chuaqui - Arlington MA, US
Russell Petter - Stow MA, US
Helen (Xiaomei) Feng - Winchester MA, US
Michael Hoemann - Marlborough MA, US
Deqiang Niu - Lexington MA, US
Dingxue Yan - Grafton MA, US
Claudio Chuaqui - Arlington MA, US
Russell Petter - Stow MA, US
Helen (Xiaomei) Feng - Winchester MA, US
International Classification:
A61K 31/55, A61K 9/00, A61K 31/502, A61K 31/517, A61K 31/438, C07D 487/10, C07D 401/14, C07D 403/14, A61P 35/00, A61P 9/12, A61P 9/10, A61P 27/02, A61P 1/16, A61P 13/12
US Classification:
424422, 51421202, 514249, 51426621, 514278, 540543, 544230, 546 15, 546 17, 546 18
Abstract:
The invention is related to compounds of formula (I) that can be used as antagonists of the TGFβ family type I receptors, Alk5 and/or Alk4, compositions and methods of use. The compounds of formula (I) can be employed in the prevention and/or treatment of diseases such as fibrosis (e.g., renal fibrosis, pulmonary fibrosis, and hepatic fibrosis), progressive cancers, or other diseases for which reduction of TGFβ family signaling activity is desirable.
Pyridinonyl Pdk1 Inhibitors
US Patent:
2010014, Jun 10, 2010
Filed:
Jul 2, 2007
Appl. No.:
12/307104
Inventors:
Kenneth Egnard Lind - Arlington MA, US
Kathy Cao - Sunnyvale CA, US
Edward Yin-shiang Lin - Chestnut Hill MA, US
Thinh Ba Nguyen - Santa Clara CA, US
Bradley T. Tangonan - San Francisco CA, US
Daniel A. Erlanson - San Francisco CA, US
Kevin Guckian - Marlborough MA, US
Robert Lowell Simmons - San Francisco CA, US
Lihong Sun - Lexington MA, US
Stig Hansen - Kensington CA, US
Nuzhat Pathan - San Diego CA, US
Lei Zhang - Cheshire CT, US
Kathy Cao - Sunnyvale CA, US
Edward Yin-shiang Lin - Chestnut Hill MA, US
Thinh Ba Nguyen - Santa Clara CA, US
Bradley T. Tangonan - San Francisco CA, US
Daniel A. Erlanson - San Francisco CA, US
Kevin Guckian - Marlborough MA, US
Robert Lowell Simmons - San Francisco CA, US
Lihong Sun - Lexington MA, US
Stig Hansen - Kensington CA, US
Nuzhat Pathan - San Diego CA, US
Lei Zhang - Cheshire CT, US
Assignee:
Sunesis Phamaceuticals - South San Francisco CA
Biogen IDEC,INC - Cambrige MA
Biogen IDEC,INC - Cambrige MA
International Classification:
A61K 31/437, C07D 471/04, C07D 487/04, C07D 413/14, A61K 31/519, A61K 31/5377, A61P 35/00
US Classification:
5142345, 546113, 546119, 544262, 544127, 514300, 514303, 5142621
Abstract:
The present invention provides pyridinonyl PDK1 inhibitors and methods of treating cancer using the same.
Heterocyclic Compounds Useful As Pdk1 Inhibitors
US Patent:
2012020, Aug 16, 2012
Filed:
Oct 5, 2010
Appl. No.:
13/499835
Inventors:
Joseph Arndt - Peabody MA, US
Timothy Chan - Newton MA, US
Kevin Guckian - Northborough MA, US
Gnanasambandam Kumaravel - Westwood MA, US
Edward Yin-Shiang Lin - Chestnut Hill MA, US
Daniel Scott - Weston MA, US
Lihong Sun - Lexington MA, US
Jermaine Thomas - Chelsea MA, US
Kurt van Vloten - Bellingham MA, US
Deping Wang - Sharon MA, US
Lei Zhang - Westford MA, US
Daniel Erlanson - San Francisco CA, US
Timothy Chan - Newton MA, US
Kevin Guckian - Northborough MA, US
Gnanasambandam Kumaravel - Westwood MA, US
Edward Yin-Shiang Lin - Chestnut Hill MA, US
Daniel Scott - Weston MA, US
Lihong Sun - Lexington MA, US
Jermaine Thomas - Chelsea MA, US
Kurt van Vloten - Bellingham MA, US
Deping Wang - Sharon MA, US
Lei Zhang - Westford MA, US
Daniel Erlanson - San Francisco CA, US
International Classification:
A61K 31/53, C07D 401/14, C07D 409/14, A61P 35/00, A61K 31/444, A61K 31/519, A61K 31/4439, A61K 31/517, C07D 471/04, C07D 401/12
US Classification:
514243, 546 82, 544279, 546119, 5462727, 544284, 5462737, 546113, 544183, 514293, 5142641, 514303, 514339, 51426621, 514338, 514300
Abstract:
The present invention provides compounds useful as inhibitors of PDK1. The present invention also provides compositions thereof, and methods of treating PDK1-mediated diseases.